Shares of Aviva plc (LON:AV – Get Free Report) have received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is GBX 538 ($6.82).
Several analysts have weighed in on AV shares. The Goldman Sachs Group initiated coverage on Aviva in a research report on Wednesday, September 18th. They issued a “buy” rating for the company. Jefferies Financial Group upped their price target on shares of Aviva from GBX 525 ($6.66) to GBX 550 ($6.97) and gave the company a “buy” rating in a report on Monday, September 9th.
Read Our Latest Stock Analysis on AV
Aviva Stock Up 1.6 %
Insider Buying and Selling
In other Aviva news, insider Pippa Lambert acquired 987 shares of Aviva stock in a transaction that occurred on Monday, September 30th. The stock was bought at an average cost of GBX 489 ($6.20) per share, for a total transaction of £4,826.43 ($6,118.70). Also, insider Amanda Blanc bought 6,250 shares of the stock in a transaction on Wednesday, September 4th. The shares were bought at an average price of GBX 499 ($6.33) per share, for a total transaction of £31,187.50 ($39,537.91). 0.17% of the stock is currently owned by company insiders.
Aviva Company Profile
Aviva plc provides various insurance, retirement, investment, and savings products in the United Kingdom, Ireland, Canada, and internationally. The company offers life insurance, long-term health and accident insurance, savings, pension, and annuity products, as well as pension fund business and lifetime mortgage products.
Recommended Stories
- Five stocks we like better than Aviva
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What Does a Stock Split Mean?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Why Are These Companies Considered Blue Chips?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Aviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviva and related companies with MarketBeat.com's FREE daily email newsletter.